Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP CLOT Trial
2024-516376-15-00Phase 4Authorised
- Sponsor
- National Institute of Cardiology
- Start
- Mar 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of heparin in mitral regurgitation (MR) and Atrial fibrillation (AFib) (2 arms), sponsored by National Institute of Cardiology. Primary endpoint: Primary efficacy composite endpoint. Planned start Mar 2022; status: authorised.
02
Drugs
heparin
03
Conditions
mitral regurgitation (MR)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2024-516376-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516376-15-00.